Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

617 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Rational parameters for antibiotic therapy in patients with cystic fibrosis.
Govan JR, Doherty C, Glass S. Govan JR, et al. Infection. 1987 Jul-Aug;15(4):300-7. doi: 10.1007/BF01644142. Infection. 1987. PMID: 3117704 Review.
A lung segmental model of chronic Pseudomonas infection in sheep.
Collie D, Govan J, Wright S, Thornton E, Tennant P, Smith S, Doherty C, McLachlan G. Collie D, et al. PLoS One. 2013 Jul 9;8(7):e67677. doi: 10.1371/journal.pone.0067677. Print 2013. PLoS One. 2013. PMID: 23874438 Free PMC article.
Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium.
Collie D, Glendinning L, Govan J, Wright S, Thornton E, Tennant P, Doherty C, McLachlan G. Collie D, et al. PLoS One. 2015 Nov 6;10(11):e0142097. doi: 10.1371/journal.pone.0142097. eCollection 2015. PLoS One. 2015. PMID: 26544950 Free PMC article.
A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa: A Proof of Concept Study.
Bedi P, Chalmers JD, Graham C, Clarke A, Donaldson S, Doherty C, Govan JRW, Davidson DJ, Rossi AG, Hill AT. Bedi P, et al. Chest. 2017 Aug;152(2):368-378. doi: 10.1016/j.chest.2017.05.017. Epub 2017 May 26. Chest. 2017. PMID: 28554732 Clinical Trial.
There was a trend toward improvement in serum C-reactive protein and serum neutrophil counts (P = .07 and P = .06, respectively). ...
There was a trend toward improvement in serum C-reactive protein and serum neutrophil counts (P = .07 and P = .06, respectively). ...
A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis.
Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. Murray MP, et al. Am J Respir Crit Care Med. 2011 Feb 15;183(4):491-9. doi: 10.1164/rccm.201005-0756OC. Epub 2010 Sep 24. Am J Respir Crit Care Med. 2011. PMID: 20870753 Clinical Trial.
Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center.
Jones AM, Dodd ME, Govan JR, Doherty CJ, Smith CM, Isalska BJ, Webb AK. Jones AM, et al. Am J Respir Crit Care Med. 2005 Feb 1;171(3):257-60. doi: 10.1164/rccm.200404-513OC. Epub 2004 Nov 12. Am J Respir Crit Care Med. 2005. PMID: 15542795
Hypermutability in environmental Pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis.
Kenna DT, Doherty CJ, Foweraker J, Macaskill L, Barcus VA, Govan JRW. Kenna DT, et al. Microbiology. 2007 Jun;153(Pt 6):1852-1859. doi: 10.1099/mic.0.2006/005082-0. Microbiology. 2007. PMID: 17526842
Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?
Macdonald D, Cuthbertson L, Doherty C, Campana S, Ravenni N, Taccetti G, Govan JR. Macdonald D, et al. J Antimicrob Chemother. 2010 Nov;65(11):2373-5. doi: 10.1093/jac/dkq342. Epub 2010 Sep 13. J Antimicrob Chemother. 2010. PMID: 20837573
Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.
Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, Heaf DP, van Saene H, Hart CA. Cheng K, et al. Lancet. 1996 Sep 7;348(9028):639-42. doi: 10.1016/S0140-6736(96)05169-0. Lancet. 1996. PMID: 8782753
617 results
Jump to page
Feedback